OncoSec jumps into TNBC CAR T therapy via Dana-Farber deal
By partnering with a Dana-Farber antibody engineering expert and leveraging the institute’s cell manufacturing capabilities, cytokine therapeutics company OncoSec is expanding into CAR T cell therapies for solid tumors. The deal highlights how manufacturing-savvy academic centers provide a cost-effective way for companies to explore new modalities that could synergize with their existing pipelines.
In a deal announced Thursday, OncoSec acquired an exclusive option to CAR T cell candidates and related IP from the lab of Wayne Marasco, a professor of cancer immunology and virology at Dana-Farber Cancer Institute. CMC and GMP manufacturing will be done through Dana-Farber Core Manipulation Cell Facility (CMCF), and early clinical studies will take place within Harvard’s hospital network...